Evaluation of the Helicobacter pylori stool antigen (HpSA) test in routine clinical practice--is it patient-friendly?
A new immunoassay has been developed to detect the presence of Helicobacter pylori antigens in stool specimens. The aim of our study was to assess the accuracy and utility of the H. pylori stool antigen (HpSA) test in routine clinical practice. Dyspeptic patients undergoing endoscopy were studied. H. pylori status was defined before treatment by CLOtest and histology, and by 13C urea breath test (UBT) after eradication therapy. A standard universal container was provided for stool collection and the HpSA test was performed by an investigator blind to the results of the other diagnostic tests. Patients also provided a venous blood sample prior to endoscopy for H. pylori serology. Sixty patients (30 M : 30 F: mean age 47 yr) were enrolled in the study. The pretreatment sensitivity, specificity, positive and negative predictive value of the HpSA test were respectively, 93%, 94%, 96%, and 90%. Twenty five patients returned for post treatment 13CUBT, but only 14 (56%) provided a stool sample for analysis. The post treatment sensitivity, specificity, positive and negative predictive value of the HpSA test were respectively, 67%, 100%, 67%, and 92%. The HpSA test was negative in 19% of the patients found positive for anti-H. pylori antibodies on serology testing. All H. pylori antibody-negative patients had a negative HpSA test. Our results suggest that the HpSA test provides accurate pretreatment diagnosis of H. pylori infection but the reliability of the test after treatment is uncertain. A potential problem with the HpSA test appears to be patient reluctance about stool handling and this could prove a significant obstacle to patient compliance and the acceptability of the test in everyday clinical practice.